Proactive Investors - Run By Investors For Investors

NetScientific’s Wanda to partner with Dignity Health

Healthcare tech investor NetScientific is to partner with a leading US hospital group to launch a software platform to improve cancer care.
NetScientific’s Wanda to partner with Dignity Health
OncoVerse is a cancer care software platform
Healthcare tech investor NetScientific (LON:NSCI) is to partner with a leading US hospital group to launch a software platform to improve cancer care.
Its operating subsidiary Wanda has inked a collaborative deal with Dignity Health to launch OncoVerse.
The digital platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce admin costs.
Dignity Health is home to nearly 9,000 physicians and more than 400 care centers spanning 21 states.
NetScientific's chief executive Francois R. Martelet said: "Wanda is the group's lead subsidiary in our digital health franchise.
"The launch of Oncoverse with Dignity Health, and its huge US network, is a significant milestone for the company and further endorses its core technology.
"This deal marks the second partnership that Wanda has secured with a leading US healthcare group since the start of 2016 as it continues to develop more platforms to better manage chronic conditions."
In January Wanda inked a deal with Chicago-based Health Resource Solutions (HRS) to provide its chronic condition digital management system.
The organisation looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals.
The first patients are expected to start using the platform in the first quarter of this year.
And this month the firm revealed one of its portfolio companies was to partner with the US National Cancer Institute for phase II clinical trials of a novel range of cancer immunotherapies.
PDS Biotechnology has signed a co-operative research and development agreement with the NCI to develop treatments using its Versamune platform for tumour-related proteins in prostate, breast, and HPV-related cancers.
NetScientific shares added  2.4% to stand at 85.5p.
View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.